scholarly journals Viral replication dynamics could critically modulate vaccine effectiveness and should be accounted for when assessing new SARS‐CoV‐2 variants

Author(s):  
Wan Yang ◽  
Jeffrey Shaman
2016 ◽  
Vol 54 (12) ◽  
pp. 1343-1404
Author(s):  
V Duhan ◽  
V Khairnar ◽  
SK Friedrich ◽  
C Hardt ◽  
PA Lang ◽  
...  

2019 ◽  
Vol 23 (2) ◽  
pp. 117-119 ◽  
Author(s):  
D. N. Paskalev ◽  
B. T. Galunska ◽  
D. Petkova-Valkova

Tamm–Horsfall Protein (uromodulin) is named after Igor Tamm and Franc Horsfall Jr who described it for the first time in 1952. It is a glycoprotein, secreted by the cells in the thick ascending limb of the loop of Henle. This protein will perform a number of important pathophysiological functions, including protection against uroinfections, especially caused by E. Сoli, and protection against formation of calcium concernments in the kidney. Igor Tamm (1922-1995) is an outstanding cytologist, virologist and biochemist. He is one of the pioneers in the study of viral replication. He was born in Estonia and died in the USA. In 1964 he was elected for a professorship in Rockefeller Institute for Medical Research, where has been working continuously. Since 1959, he became a head of the virology lab established by his mentor and co-author Franc Horsfall. In the course of studies on the natural inhibitor of viral replication, Tamm and Horsfall isolated and characterized biochemically a new protein named after their names. Franc Lappin Horsfall Jr (1906-1971) was a well-known clinician and virologist with remarkable achievements in internal medicine. He was born and died in the USA. He worked in the Rockefeller Hospital from 1934 to 1960, then in the Center for Cancer Research at the Sloan-Kettering Institute. Here he was a leader of a research team studying the molecular mechanisms of immunity, the effects of chemotherapy with benzimidazole compounds (together with I. Tamm), coxsackie viruses, herpes simplex virus, etc. 


2012 ◽  
pp. 107-113
Author(s):  
Van Huy Tran ◽  
Hoai Phong Nguyen

Background: The recent studies concerning antiviral therapy in HBV-related cirrhosis showed the promising results. This study is aimed at assessing efficacy of lamivudine in patients with HBV-related cirrhosis. Patients and methods: 41 patients with HBsAg positive-cirrhosis and evidence of viral replication were enrolled in the study. Lamivudine is given 100 mg per day and the follow-up is 12 months. Results: The rates of HBV DNA undetectable was 58.53%, 68.29% and 87.80% after 36.6 and 12 months, respectively. The rate of HBeAg loss and HBeAg seroconversion are 57.14% and 35.71%. Child-Pugh scores decreased significantly after 6 and 12 months. The complications of cirrhosis were infrequent. Conclusion: Lamivudine appeared effective and safe in HBV-related hepatic cirrhosis.


Sign in / Sign up

Export Citation Format

Share Document